vs

Side-by-side financial comparison of Colgate-Palmolive (CL) and CELESTICA INC (CLS). Click either name above to swap in a different company.

Colgate-Palmolive is the larger business by last-quarter revenue ($5.2B vs $4.0B, roughly 1.3× CELESTICA INC). CELESTICA INC runs the higher net margin — 5.2% vs -0.7%, a 5.9% gap on every dollar of revenue. On growth, CELESTICA INC posted the faster year-over-year revenue change (52.8% vs 5.8%). Colgate-Palmolive produced more free cash flow last quarter ($1.3B vs $137.9M). Over the past eight quarters, CELESTICA INC's revenue compounded faster (35.4% CAGR vs 1.6%).

The Colgate-Palmolive Company, commonly known as Colgate-Palmolive, is an American multinational consumer products company headquartered on Park Avenue in Midtown Manhattan, New York City. The company specializes in the production, distribution, and provision of household, health care, personal care, and veterinary products.

Celestica Inc. is a Canadian multinational design, manufacturing, hardware platform, and supply chain electronics manufacturing services (EMS) company, which is headquartered in Toronto, Ontario. The company operates in 50 sites across 15 countries.

CL vs CLS — Head-to-Head

Bigger by revenue
CL
CL
1.3× larger
CL
$5.2B
$4.0B
CLS
Growing faster (revenue YoY)
CLS
CLS
+47.0% gap
CLS
52.8%
5.8%
CL
Higher net margin
CLS
CLS
5.9% more per $
CLS
5.2%
-0.7%
CL
More free cash flow
CL
CL
$1.1B more FCF
CL
$1.3B
$137.9M
CLS
Faster 2-yr revenue CAGR
CLS
CLS
Annualised
CLS
35.4%
1.6%
CL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CL
CL
CLS
CLS
Revenue
$5.2B
$4.0B
Net Profit
$-36.0M
$212.3M
Gross Margin
60.2%
10.8%
Operating Margin
1.7%
6723.5%
Net Margin
-0.7%
5.2%
Revenue YoY
5.8%
52.8%
Net Profit YoY
-104.9%
146.3%
EPS (diluted)
$-0.04
$1.83

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CL
CL
CLS
CLS
Q1 26
$4.0B
Q4 25
$5.2B
$3.7B
Q3 25
$5.1B
$3.2B
Q2 25
$5.1B
$2.9B
Q1 25
$4.9B
$2.6B
Q4 24
$4.9B
Q3 24
$5.0B
$2.5B
Q2 24
$5.1B
$2.4B
Net Profit
CL
CL
CLS
CLS
Q1 26
$212.3M
Q4 25
$-36.0M
$267.5M
Q3 25
$735.0M
$267.8M
Q2 25
$743.0M
$211.0M
Q1 25
$690.0M
$86.2M
Q4 24
$738.0M
Q3 24
$737.0M
$89.5M
Q2 24
$731.0M
$95.0M
Gross Margin
CL
CL
CLS
CLS
Q1 26
10.8%
Q4 25
60.2%
11.8%
Q3 25
59.4%
13.0%
Q2 25
60.1%
12.8%
Q1 25
60.8%
10.3%
Q4 24
60.3%
Q3 24
61.1%
10.4%
Q2 24
60.6%
10.6%
Operating Margin
CL
CL
CLS
CLS
Q1 26
6723.5%
Q4 25
1.7%
8.6%
Q3 25
20.6%
10.2%
Q2 25
21.1%
9.4%
Q1 25
21.9%
4.9%
Q4 24
21.5%
Q3 24
21.2%
5.5%
Q2 24
21.6%
5.6%
Net Margin
CL
CL
CLS
CLS
Q1 26
5.2%
Q4 25
-0.7%
7.3%
Q3 25
14.3%
8.4%
Q2 25
14.5%
7.3%
Q1 25
14.1%
3.3%
Q4 24
14.9%
Q3 24
14.6%
3.6%
Q2 24
14.5%
4.0%
EPS (diluted)
CL
CL
CLS
CLS
Q1 26
$1.83
Q4 25
$-0.04
$2.29
Q3 25
$0.91
$2.31
Q2 25
$0.91
$1.82
Q1 25
$0.85
$0.74
Q4 24
$0.89
Q3 24
$0.90
$0.75
Q2 24
$0.89
$0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CL
CL
CLS
CLS
Cash + ST InvestmentsLiquidity on hand
$1.4B
$378.0M
Total DebtLower is stronger
$7.8B
Stockholders' EquityBook value
$54.0M
$2.1B
Total Assets
$16.3B
$8260.0B
Debt / EquityLower = less leverage
145.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CL
CL
CLS
CLS
Q1 26
$378.0M
Q4 25
$1.4B
$595.6M
Q3 25
$1.3B
$305.9M
Q2 25
$1.2B
$313.8M
Q1 25
$1.1B
$303.0M
Q4 24
$1.3B
Q3 24
$1.2B
Q2 24
$1.1B
Total Debt
CL
CL
CLS
CLS
Q1 26
Q4 25
$7.8B
$750.5M
Q3 25
$756.7M
Q2 25
$848.6M
Q1 25
$915.0M
Q4 24
$7.0B
Q3 24
Q2 24
Stockholders' Equity
CL
CL
CLS
CLS
Q1 26
$2.1B
Q4 25
$54.0M
$2.2B
Q3 25
$856.0M
$2.0B
Q2 25
$702.0M
$1.8B
Q1 25
$363.0M
$1.6B
Q4 24
$212.0M
Q3 24
$435.0M
$1.8B
Q2 24
$123.0M
$1.8B
Total Assets
CL
CL
CLS
CLS
Q1 26
$8260.0B
Q4 25
$16.3B
$7.2B
Q3 25
$17.5B
$6.6B
Q2 25
$17.5B
$6.2B
Q1 25
$16.6B
$5.8B
Q4 24
$16.0B
Q3 24
$16.8B
Q2 24
$16.5B
Debt / Equity
CL
CL
CLS
CLS
Q1 26
Q4 25
145.17×
0.34×
Q3 25
0.37×
Q2 25
0.48×
Q1 25
0.59×
Q4 24
33.04×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CL
CL
CLS
CLS
Operating Cash FlowLast quarter
$1.5B
$356.3M
Free Cash FlowOCF − Capex
$1.3B
$137.9M
FCF MarginFCF / Revenue
24.4%
3.4%
Capex IntensityCapex / Revenue
3.4%
Cash ConversionOCF / Net Profit
1.68×
TTM Free Cash FlowTrailing 4 quarters
$3.6B
$502.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CL
CL
CLS
CLS
Q1 26
$356.3M
Q4 25
$1.5B
$250.6M
Q3 25
$1.3B
$126.2M
Q2 25
$884.0M
$152.4M
Q1 25
$600.0M
$130.3M
Q4 24
$1.3B
Q3 24
$1.2B
$122.8M
Q2 24
$990.0M
$99.6M
Free Cash Flow
CL
CL
CLS
CLS
Q1 26
$137.9M
Q4 25
$1.3B
$155.9M
Q3 25
$1.1B
$88.9M
Q2 25
$776.0M
$119.9M
Q1 25
$476.0M
$93.6M
Q4 24
$1.1B
Q3 24
$1.0B
$76.8M
Q2 24
$873.0M
$62.7M
FCF Margin
CL
CL
CLS
CLS
Q1 26
3.4%
Q4 25
24.4%
4.3%
Q3 25
21.6%
2.8%
Q2 25
15.2%
4.1%
Q1 25
9.7%
3.5%
Q4 24
21.9%
Q3 24
20.5%
3.1%
Q2 24
17.3%
2.6%
Capex Intensity
CL
CL
CLS
CLS
Q1 26
Q4 25
3.4%
2.6%
Q3 25
3.0%
1.2%
Q2 25
2.1%
1.1%
Q1 25
2.5%
1.4%
Q4 24
3.7%
Q3 24
2.7%
1.8%
Q2 24
2.3%
1.5%
Cash Conversion
CL
CL
CLS
CLS
Q1 26
1.68×
Q4 25
0.94×
Q3 25
1.72×
0.47×
Q2 25
1.19×
0.72×
Q1 25
0.87×
1.51×
Q4 24
1.72×
Q3 24
1.58×
1.37×
Q2 24
1.35×
1.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CL
CL

Other$3.0B58%
Pet Nutrition$1.2B23%
Oral Personal And Home Care$1.0B20%

CLS
CLS

Segment breakdown not available.

Related Comparisons